anti-PIAS1 (PIAS1) Antikörper

Mouse (Murine) Protein Inhibitor of Activated STAT, 1 (PIAS1) Interaktionspartner

1. These findings demonstrate the crucial role of PIAS1-mediated PPARgamma SUMOylation in protecting against myocardial ischemia-reperfusion injury.

2. these results indicate that PIAS1 is a positive regulator of MYC.

3. PIAS1 overexpression exacerbated mutant Huntingtin-associated phenotypes and aberrant protein accumulation

4. Pias1 expression in primary myoblasts enhances the induction of cardiac muscle genes MyoD, Myogenin and Myomaker. Endothelial cell specific inactivation of Pias1 in vivo impairs yolk sac erythrogenesis, angiogenesis and recapitulates loss of myocardium muscle mass. Pias1 is an essential gene for YS erythropoiesis and vasculogenesis in vivo.

5. Data suggest overexpression of Pias1 in white adipose tissue (WAT) of obesity/prediabetes improves insulin resistance; knockdown of Pias1 in normal WAT leads to insulin resistance; Pias1 expression in WAT is down-regulated by c-Jun N-terminal kinase.

6. Between the E3 SUMO ligase PIAS1 and STAT-3.

7. Knockdown of PIAS1 in astrocytes impairs the accumulation of nuclear STI1 in response to irradiation. Moreover, a PIAS1 mutant lacking the STI1 binding site is unable to increase STI1 nuclear retention.

8. A novel role of PIAS1 in maintaining the quiescence of dormant hematopoietic stem cells and in the epigenetic repression of the myeloerythroid program.

9. The present study showed that PIAS1 functions as a SUMO E3 ligase of C/EBPbeta to regulate adipogenesis.

10. Piasy represses the synergistic activation of PITX2 with interacting co-factors and Piasy represses Pias1 activation of PITX2 transcriptional activity.

11. MAPK-activated protein kinase-2 limits endothelial inflammation via the PIAS1 S522 phosphorylation-mediated increase in PIAS1 transrepression and SUMO ligase activity.

12. Results suggest that PIAS1 may serve as a lipogenic regulator by negatively modulating liver X receptors (LXRs) in a SUMOylation-independent manner.

13. PIAS1 modifies covalent modification of Blimp-1 by SUMO-1 at lysine 816.

14. PIAS1 negatively regulates ubiquitination of Msx1 homeoprotein independent of its SUMO ligase activity.

15. FOXL2 interacts with PIAS1 and UBC9, and sumoylated in both human and mouse

16. PIAS1 restricts the differentiation of natural T(reg) cells by maintaining a repressive chromatin state of the Foxp3 promoter.

17. Pias1-dependent SUMOylation influences Gli protein activity

18. protein inhibitor of activated Stat1 (PIAS1) interacts with the tetramerization and C-terminal regulatory domains of p53 in yeast two-hybrid analyses

19. Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators.

20. PIAS1 has a role in sumoylation of focal adhesion kinase and activates its autophosphorylation

Human Protein Inhibitor of Activated STAT, 1 (PIAS1) Interaktionspartner

1. PIAS1expression of PIAS1 gene was increased in patients with MS compared to healthy subjects; also, there was a significant correlation between the expression of PIAS1 and PIAS2 genes with disease severity of multiple sclerosis

2. A novel function of p14ARF to inhibit PIAS1 by enhancing SUMOylation.

3. These findings demonstrate the crucial role of PIAS1-mediated PPARgamma SUMOylation in protecting against myocardial ischemia-reperfusion injury.

4. Rad18, independently of its ubiquitin ligase activity, promotes DNA polymerase eta SUMOylation by facilitating its interaction with its SUMO ligase PIAS1 and is required for DNA polymerase eta function at difficult to replicate loci.

5. PIAS1 as a key regulator of Epstein-Barr Virus lytic replication. PIAS1 acts as an inhibitor for transcription factors involved in lytic gene expression.

6. these results indicate that PIAS1 is a positive regulator of MYC.

7. PIAS1 is a prognostic biomarker in breast cancer

8. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

9. PIAS1 overexpression exacerbated mutant Huntingtin-associated phenotypes and aberrant protein accumulation

10. HBs protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways

11. identified the SUMO ligase PIAS1 as a constituent PML-NB antiviral protein. This finding distinguishes a SUMO ligase that may mediate signaling events important in promyelocytic leukemia nuclear body mediated intrinsic immunity.

12. PIAS1 enhances p300 recruitment to c-Myb-bound sites through interaction with both proteins. In addition, the E3 activity of PIAS1 enhances further its coactivation

13. Results show that apocrine breast cancer and prostate cancer cells share a core AR cistrome and target gene signature linked to cancer cell growth, and PIAS1 plays a similar coregulatory role for AR in both cancer cell types.

14. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4

15. Data demonstrate that PIAS1 interacts with TRF2 and mediates its sumoylation serving as a molecular switch that controls the level of TRF2 at telomeres.

16. the expression of SENP8, SAE1, PIAS1, PIAS2 and ZMIZ1 is deregulated in the majority of PTC tissues, likely contributing to the PTC phenotype.

17. Our data suggest that necdin suppresses PIAS1 both by inhibiting SUMO E3 ligase activity and by promoting ubiquitin-dependent degradation.

18. the presented data indicate that PIAS1 is crucial for parental and docetaxel resistant prostate cancer cell survival

19. Elevated PIAS1 expression was observed in breast tumor samples.

20. PIAS1 is the E3 ligase responsible for SUMOylation of HMGN2.